Introduction
Bipolar disorder (BP) is relatively common, with bipolar-I illness affecting 0.5-1% of the population. The heritability of BP is high, around 80%; 1 nevertheless, finding genes that contribute to the susceptibility to this disorder has proven elusive. This is almost certainly because many genes of small effect size (that is, conferring a relative risk of less than two) contribute to the liability to develop the disorder.
Strategies for elucidating specific genetic bases for BP include linkage and association methods. In fact, two approaches have been mainly employed to identify genes to be investigated in BP, as well as in other complex diseases. First, the so-called 'functional candidate approach,' based on the selection of genes that are thought to be involved in the biological processes implicated in the disease. Usually, researchers derive their hypotheses from the knowledge of neurophysiologic alterations associated with the disorder, from animal models and pharmacological studies, elucidating the mechanisms of action of psychotropic treatments. An example of this approach considers the brain-derived neurotrophic factors (BDNFs), which has been investigated in mood disorders because, on the one hand, animal studies showed that development of cortical neuronal circuits was related to the expression of brain-BDNF 2 and, on the other hand, there was evidence of reductions in the volume of the hippocampus in subjects with a history of depression. 3 Another example considers the well-known serotonin transporter gene (SLC6A4), which has been investigated in depressive disorders because its product is the target of action of serotonin selective reuptake inhibitors, the most widely employed antidepressant drugs currently prescribed for major depression.
The alternative approach is based on the selection of genes that are located in regions associated with BP in linkage studies, the so-called 'positional candidate approach.' This approach has been employed, for example, to select the G30 gene (also called DAOA), as it is located in the 13q33, a region that has been reported as positively linked to both schizophrenia 4 and BP. 5 Unfortunately, results from linkage and association studies are not always easily comparable and at present a comprehensive coverage of available evidence is still lacking, despite many efforts of academic and government institutions. The present paper reviews current research from linkage and association studies on the molecular bases of BP, with the aim to point out genomic regions of interest and promising genes that have to be further investigated, other than summarizing the current state of the art. Further, we aimed to indicate new potential interesting genes, located in genome 'hot regions' for BP and being expressed in the brain. We will discuss the utility to combine linkage, association and other approaches, to clarify the genetic mechanisms of BP.
Methods
We reviewed published studies on linkage and association studies in BP till December 2007, employing the Medline database (http://www.ncbi.nlm.nih. gov/) and entering the following key words: BP, affective disorder, depressive disorder, gene, genetics, association, linkage and chromosome 1 to X. For each gene/region found positive in BP investigations, we also searched for other studies investigating the specific gene/region, entering BP/affective disorder/ depressive disorder and gene/region/chromosome. We considered only papers written in English and defining BP according to diagnostic and statistical manual of mental disorders (DSM) criteria. Metaanalyses and studies combining results of previous investigations were considered as a summary of preceding works. In total, 345 studies were selected (97 linkage studies and 248 association studies--5 including both methodologies).
Positive linkage was established when the marker obtained LOD score of at least 2 or a nominal P-value lower than 0.05. Significance in association studies was as well considered with a nominal P-value lower than 0.05. We precisely localized regions where positive linkage was found by the NCBI Map viewer (http://www.ncbi.nlm.nih.gov/mapview/). Genes located in interesting areas and being expressed in the brain, not yet investigated in association studies, were identified by the 'Entrez gene', 'Unigene' databases (http://www.ncbi.nlm.nih.gov/sites/entrez), and the 'Human Protein Reference Database' (http:// www.hprd.org). For this, we entered the specific region in 'Entrez gene,' we looked at 'expression profile' in 'Unigene' and classified their product for molecular class and biological process by the 'Human Protein Reference Database.'
Review of linkage studies and new positional candidate genes
Many linkage studies have been performed since the 1990s and a huge amount of data has been collected.
Areas that have been associated with BP are summarized in Table 1 and Figure 1 .
Some areas throughout the genome have been repeatedly associated with BP and thus they represent 'hot regions.' However, only few of these contain genes that have been investigated in association studies. These regions are 4p16.1, where wolframin gene (WFS1) and some recently investigated genes, such as WD repeat-containing protein 1 (WDR1) and protein phosphatase 2 (PPP2R2C) are located; 11p15.5, where dopamine receptor D4 (DRD4) and tyrosine hydroxylase (TH) are located; 12q24.31, where nitric oxide synthase 1 (NOS1) is located; 18p11.21, where myo-inositol monophosphatase 2 (IMPA2) is located; 21q22.2-3, where transient receptor potential 3 (TRPM3) is located and 22q12.3, where synapsin III (SYN3) is located.
Other 'hot regions' are 5p15.33, 6q21, 8q24.22, 10q26.2, 13q32.1-3, 17q25.3, 18p11.31, 18q22-23, 20q13.33, Xq26.1. Nevertheless, to our knowledge, positive findings for genes located within these latter areas have been never reported in association studies. For this purpose, we performed a research for genes located in all these areas ('Entrez gene' database), which are known to be expressed in the brain (expression profile, 'Unigene' database) and known with respect to the biological process they are involved in ('Human Protein Reference Database'). In Table 2 , the reader can find a list of genes select. Some of these genes are very close to markers employed in linkage studies and found positive; in some cases positive markers are located exactly within the gene.
A number of other interesting areas have been also reported in the literature, and the reader can find a comprehensive summary in Table 1 .
Serotonin-related genes
Certainly, one of the most widely investigated genes in BP is serotonin transporter (SLC6A4). This gene is located in 17q11.1-q12, a region found positive in two linkage studies. Positive results have been obtained with respect to a 48 bp promoter polymorphism (SERTPR), and four consecutive meta-analyses confirmed the finding. Though less widely, a VNTR element in the second intron has also been investigated, and it was found positive in one meta-analytic study, but not in other two.
Another gene consistently associated with BP, but not located in a region found in positive linkage with BP, is neuronal tryptophan hydroxylase (TPH2), which codes for the rate-limiting enzyme in the biosynthesis of serotonin in the central nervous system. 102 Single nucleotide polymorphisms (SNPs) within the gene have been associated with BP in five independent studies, while two studies failed to report associations. Mainly negative results have been instead reported with respect to tryptophan hydroxylase 1 (TPH1); however, this gene seems to be mostly expressed in peripheral tissues. The following serotonin receptors' genes have been investigated in more than one study: serotonin receptor 1A (HTR1A), serotonin receptor 2A (HTR2A), serotonin receptor 2C (HTR2C) and serotonin 7 receptor (HTR7). HTR1A, after a first negative report, was found associated with BP in two studies with respect to a dinucleotide tandem repeats (CAn/ GTn) and a G > A SNP in exon 1. Some evidence, though contrasting, does also exist for HTR2A, located in the positive region 13q14-q21. Association has been reported for 516C > T, 1438G > A and 62428C > T (rs6313) polymorphisms, while mainly negative findings were reported for þ 74C > A, 102T/ C, 1354C/T (except Ranade et al. 104 ) and His452Tyr polymorphisms. With respect to HTR2C, two studies reported negative association for a cys23-ser23 polymorphism in exon 4, while a third study found a positive association. Other variants in the 5 0 regulatory region of the gene did not give positive results, whereas positive association for the þ 12C > G SNP in exon 3 was observed in one study. Finally, three studies focused on HTR7 and two of these failed to find an association with BP; however, the gene is located in the interesting region 10q21-q24, thus further investigation may be required.
In conclusion, consistent association has been found for SLC6A4 and TPH2. HTR1A, HTR2A and HTR2C seem to be promising candidate genes as well, while HTR7 mainly gave negative results. Nevertheless, further investigation is required. Other serotoninergic genes of interest, needing additional investigation, are listed in Tables 3 and 4 .
Dopaminergic genes
A second gene widely investigated and consistently associated with BP is DRD4, located in a region found in positive linkage with BP (11p15.5). In particular, a VNTR in the third exon was repeatedly reported associated with BP and a recent meta-analysis confirmed the finding. Another promising dopamine receptor gene is dopamine receptor D1 (DRD1), which was initially reported as negative in studies investigating the promoter -48A/G polymorphism, except for two positive reports following. However, other polymorphisms within the gene were investigated and while some did not show association with BP, two studies on haplotypes reported positive results.
Dopamine transporter gene (SLC6A3) is a third dopaminergic gene reliably involved in BP. Whereas first studies investigating the 40 bp VNTR in the 3 0 untranslated region mainly reported negative findings, positive results were obtained analyzing other polymorphisms, such as the À67A/T in Asiatic populations, and haplotypes located in the promoter region and at the end region of the gene.
Some other dopaminergic genes, found positively associated in at least one study, were extensively investigated but studies mainly failed to find them associated with BP. This was the case of dopamine receptor D3 (DRD3), dopa decarboxylase gene (DDC), involved in the synthesis of both dopamine and serotonin; and TH, located in the hot region 11p15.5 and involved in the conversion of phenylalanine to dopamine. In conclusion, studies support the involvement of dopaminergic genes such as DRD4 and SLC6A3 in BP. DRD1 is another promising candidate, though less confirmed. Other dopaminergic genes of interest and needing further investigation are listed in Table 4 .
g-Aminobutyric acid-related genes Among g-aminobutyric acid (GABA) pathway's genes, g-aminobutyric acid A receptor, a-1 (GABRA1) gave promising evidence. After a first negative report, GABRA1 was found associated with BP in one study employing both case-control and family-based association studies: in particular, this study reported positive findings for the 156T > C SNP. Recently, 12 SNPs within the gene have been analyzed but found negative.
g-Aminobutyric acid A receptor, a-5 (GABRA5) encodes a GABA-a receptor having a unique benzodiazepine pharmacology. 351 Two studies, in both Caucasians and Asians, reported positive associations with BP, analyzing different polymorphisms within the gene. Instead, mainly negative results were obtained analyzing g-aminobutyric acid A receptor, a-3 (GABRA3), though it is located in an interesting region for BP (Xq28).
In conclusion, though GABAergic genes did not provide strong evidence in BP; GABRA1 and GA-BRA5 can be considered promising candidate genes. Other GABAergic genes of interest, needing further investigation, are listed in Table 4 .
Acetylcholine-related genes
The cholinergic system has been poorly investigated in BP. However, the cholinergic receptor, neuronal nicotinic, a polypeptide 7 (CHRNA7), has been suggested as a promising candidate gene. It encodes for a nicotinic acetylcholine receptor, previously associated with the risk to develop schizophrenia. 352 In BP, two studies reported positive associations in both Caucasians and Asians, while a third investigation in a Caucasian population reported a negative finding. Other acetylcholinergic genes of interest, needing further investigation, can be found listed in Table 4 .
Glutamate-related genes
This system has also been poorly investigated in BP. However, a gene pertaining to the glutamatergic pathway has been consistently associated with BP. This is the case of D-amino acid oxidase activator (DAOA), located in a region in positive linkage with BP (13q33.2). DAOA plays a role in the activation of N-methyl-D-aspartate receptors, members of the glutamate receptor channel superfamily, which are implicated in both schizophrenia and BP. 4 ,239 A number of SNPs within this gene have been positively associated with BP in six independent studies in Caucasians. Recently, a large study reported a significant association between a polymorphism close to DAOA (rs1981272) and BP.
N-Methyl-D-aspartate 2B (GRIN2B) encodes for a N-methyl-D-aspartate receptor and it is another promising gene in BP. It is involved in long-term potentiation and in activity-dependent increase in the efficiency of synaptic transmission and it is thought to underlie certain kinds of memory and learning. 353 Recently, two studies investigated this gene in BP, reporting positive findings, particularly in association with psychotic symptoms.
Another gene of interest is dystrobrevin-binding protein 1 (DTNBP1), expressed in all principal neuronal populations of the hippocampus; the protein is located in presynaptic axon terminals of the glutamatergic neurons. A significant reduction of dysbindin-1 in the terminal fields of intrinsic glutamatergic connections of the hippocampus was observed in schizophrenic subjects. 354 In BP, SNPs within DTNBP1 were found associated with the disease in three Caucasian samples and two Korean populations; furthermore, a polymorphism close to the gene (rs742206) has been reported associated with BP in a large study in Caucasians.
Given these first observations, particularly with respect to the reliable involvement of DAOA in BP, other genes of the glutamatergic pathways have to be taken into account in the investigation of genetics of BP.
Other amines' metabolism-related genes Monoamine oxidase A (MAOA) is located in the positive region Xp11.3 and is a widely investigated gene in BP, because MAOA protein oxidizes neurotransmitters such as serotonin, norepinephrine and dopamine. In the late 1990s, a meta-analysis and one study on five pooled samples confirmed the association between a CA repeat microsatellite in intron 2 and BP, in both Caucasians and Asians. A second repeat polymorphism in the promoter of MAOA was reported associated in BP in one study on five pooled samples, but one study in Asians did not report a significant association and two following studies in Caucasian were negative for this promoter variant. Recently, the haplotype composed of the CA repeat microsatellite and the promoter polymorphism was found positive in Caucasian BP.
Catechol-O-methyltransferase (COMT) is another promising candidate gene, as it encodes for an enzyme that catalyzes the degradation of catecholamines, including the neurotransmitters dopamine, epinephrine and norepinephrine. The gene obtained controversial results. The largely investigated 158Val/ Met polymorphism was found not associated with BP, except in some studies. However, other polymorphisms were investigated and two studies reported positive association investigating rs165599; other polymorphisms (rs2097603, À941T/G) were associated with BP as well.
Signal transduction-related genes
A gene of interest is IMPA2, located in a region consistently associated with BP (18p11.21). Myoinositols play a crucial role in the phosphatidylinositol signaling pathway, which is thought to be In bold, meta-analysis or large studies on pooled sample. modified by lithium. Three studies investigated this gene in BP and two found a positive involvement of SNPs À461C > T and À207T > C in Arabic and Japanese populations. However, one study in Caucasians failed to find a positive association between À461C > T and BP, and other polymorphisms ( þ 97G > A, þ 99G > A and rs3786282A > C) as well. Recently, another negative report has been published. Phospholipase C g 1 isoform A (PLCG1) encodes an enzyme that mediate the production of secondmessenger molecules. To our knowledge, only two studies investigated this gene in BP, both focusing on an intronic dinucleotide repeat polymorphism. The two studies reported small but positive associations in lithium responders.
Another gene of interest is transient receptor potential cation channel, subfamily M, member 2 (TRPM2), located in a 'hot region' (21q22). TRPM2 proteins are thought to be subunits of capacitative calcium entry channels, which mediate calcium influx into cells. 355 A first positive finding was soon followed by two independent but contrasting replications.
Regulator of G protein signaling 4 (RGS4), though located in an interesting region (1q23.3), has been poorly investigated. It encodes proteins that accelerate the GTPase activities of G protein a-subunits, thus driving G proteins into their inactive GDP-bound forms. Nevertheless, preliminary studies failed to find an involvement of this gene in BP.
Synaptobrevin-like 1 (SYBL1) is located in the pseudoautosomal region Xq28. Synaptobrevin is an intrinsic membrane protein of small synaptic vesicles and may play a role in the molecular events underlying neurotransmitter release and vesicle recycling. SYBL1 is subjected to X inactivation and it is inactive on Y chromosome, thereby maintaining dosage compensation. A G-C SNP in intron 5 was reported associated with BP finding have been replicated in two independent samples.
In conclusion, some genes involved in signal transduction can be involved in susceptibility for BP or related features. Further investigation is certainly required and other genes have to be taken into account. Some of them can be found listed in Table 4 .
Cell maintenance and/or cell growth-related genes A promising candidate gene in BP is glycogen synthase kinase 3-b gene (GSK3B), involved in energy metabolism, neuronal cell development and body pattern formation. 356 The mostly investigated T-50C polymorphism was at first associated with BP, but then negative reports were published. Nevertheless, an increased frequency in BP of a duplication in copy number variation, probably affecting 3 0 -coding elements, has been reported recently.
BDNF is located in 11p13, not far from a marker associated with BP (D11S987 18 ). This gene seems to be consistently associated with BP. BDNF codes for a prosurvival factor induced by cortical neurons that is necessary for survival of striatal neurons in the brain. 357 A G > A SNP at nucleotide 196 results in a val66-to-met change in the 5 0 pro-region of the human BDNF protein. This polymorphism has been associated with BP in nine independent studies in Caucasians. Nevertheless, six other studies reported negative findings, and a recent meta-analysis failed to support an involvement of this polymorphism in BP. Other studies, investigating a microsatellite located approximately 1.0 kb upstream of the translation initiation site (BDNF-LCPR), reported positive association in three independent samples. Recently, a polymorphism (rs4923460) in the BDNF opposite strand (BDNFOS), has been found positive in a large Caucasian BP sample. To summarize, eleven studies confirmed the association between BDNF and BP, particularly in Caucasians.
Another gene reliably involved in BP is neuregulin 1 gene (NRG1), previously found positive in schizophrenia. 358 The gene is expressed predominantly in early embryogenesis; 359 its product promotes the proliferation and survival of the oligodendrocyte, and the myelinating cell of the central nervous system. 360, 361 A number of SNPs within NRG1 were found associated with BP in three different studies. Recently, a large study in Caucasians reported a positive association between a polymorphism closed to NRG1 (rs1487152) and BP, though another recent paper did not find any association.
Again, a gene consistently associated with BP is disrupted in schizophrenia 1 (DISC1), located in 1q42.1, close to a region found in positive linkage with BP (1q42.2). DISC1 encodes an 854-amino-acid protein, which interact with a variety of cytoskeletal proteins, some of these associated with cortical development. After a first negative report, a number of SNPs within the gene have been associated with BP in four independent studies.
Cell adhesion molecule, neural, 1 (NCAM1) is a promising candidate in BP. It encodes a protein that is important in brain cell development and in adhesion, cell signaling and neuroplasticity in the adult brain. Polymorphisms within the gene have been associated with BP in a Japanese sample and, recently, in a Caucasian one.
Angiotensin I-converting enzyme isoform 1 (ACE) seems to be less consistently involved in BP. It plays an important role in blood pressure regulation and electrolyte balance by hydrolyzing angiotensin I into angiotensin II, a potent vasopressor, and aldosteronestimulating peptide; it has been extensively investigated but mainly negative results were obtained.
Finally, tumor necrosis factor (TNF), which encodes multifunctional proinflammatory cytokine, has been poorly investigated, but preliminary findings mainly failed to find an involvement of this gene in BP.
In conclusion, genes involved in cell growth and maintenance may play an important role in the development of BP. In fact, three important genes, BDNF, NRG1 and DISC1 showed consistent association with the disorder.
Transcription factor-related genes Only two genes related to transcription have been found positive in at least one study, but they both then received negative replications. These genes are transcription factor 4 (TCF4), encoding proteins that bind to a motif of the glucocorticoid response element (GRE) and X-box binding protein 1 (XBP1), encoding a protein that is thought to act as a transcription factor by recognizing the X2 promoter element of some class II major histocompatibility complex genes (HLA). Nevertheless, this pathway needs more attention and the reader can find possibly interesting genes listed in Table 4 .
Circadian rhythm-related genes Period homolog 3 (PER3), located in a region linked with BP (1p36.33), is involved in the regulation of circadian rhythms in physiology and behavior 362 and it has been shown to be a promising candidate gene for susceptibility of BP. To our knowledge, only two studies investigated this gene in association with BP and both reported positive findings.
Another promising gene is aryl hydrocarbon receptor nuclear translocator-like (ARNTL), which encodes the protein Arntl that dimerizes with the circadian locomotor output cycles kaput (Clock) protein. ClockArntl heterodimers appear to drive the PER transcriptional oscillations. 363 In BP, two studies reported positive association with some SNPs within the gene.
Genes needing further investigation
The present review also aimed to give some suggestions for future research. In fact, there are a number of genes that will need attention: genes that gave preliminary controversial results and genes that have been found positive but need replication in independent samples. These genes are summarized in Table 4 , where their symbol, according to OMIM (http://www. ncbi.nlm.nih.gov/entrez/query.fcgi?db = OMIM), their position and references, are reported. Furthermore, in Table 2 , a lot of genes that were never investigated can be found for further studies.
Summary
Some genes have been consistently associated with BP, while other showed promising results. What is particularly interesting is the fact that genes we found reliably involved in BP pertain to different pathways: serotonin (SLC6A4 and TPH2), dopamine (DRD4 and SLC6A3), glutamate (DAOA and DTNBP1), cell growth and/or maintenance pathways (NRG1, DISC1 and BDNF), supporting the idea that BP is a complex disorder, involving different biological processes, probably interacting with each other. There is less evidence with respect to genes pertaining to GABA, acetylcholine, signal transduction pathways, transcription factors and circadian rhythms. Nevertheless, these last pathways have been much less investigated than those providing consistent results, thus further attention needs to be paid to these biological systems as well.
Discussion
The present paper reviewed current research from linkage and association studies on BP, with the aim to point out genomic regions of interest and promising genes that have to be further investigated, other than summarizing the current state of the art. In fact, in the recent years, a large number of linkage and association studies have been conducted, producing an extremely large number of findings. Nevertheless, results from linkage and association studies are not always easily comparable and at present a comprehensive coverage of available evidence is still lacking.
In this review, we at first outlined a number of 'hot regions,' as indicated by linkage studies on families. In some of these areas, interesting genes are actually located that have been investigated in association studies. However, many other genes are located in these regions and they have never been investigated. To provide the reader a preliminary map of future potential candidate genes, we searched for genes known to be expressed in the brain and located in these interesting areas. This is a common strategy when searching for 'positional candidate genes'; nevertheless, a review of them, though preliminary, limited to some areas and to known brain-expressed genes, does not exist.
Second, we reviewed the literature for functional and positional candidate genes investigated in casecontrol and family-based association studies. We found a number of genes consistently associated with BP, such as SLC6A4, TPH2, DRD4, SLC6A3, DAOA, DTNBP1, NRG1, DISC1 and BDNF. Other genes are particularly promising, such as DRD1, HTR1A, HTR2A, HTR2C, COMT, MAOA, GABRA1, GABRA5 and others. Further research is needed regarding these genes; much more with respect to other genes less investigated or that never received independent replications. Overall, it is our advise that future studies should investigate a panel of SNPs, possibly covering the entire length of the gene, to cover as much as possible all variations potentially affecting the expression of the gene or the nature of its product (functional variations). We presented a similar approach for HTR1A. 364 High-throughout genotyping and microarray-based technologies allow many polymorphisms to be examined across a whole region of interest; nevertheless, the researcher has to be aware of the high risk of false positives when analyzing a large number of polymorphisms. The traditional stringent significance cutoff may not be appropriate for low-risk conferring variants.
Furthermore, as already underlined by Hayden and Nurnberger, 365 different approaches will probably be necessary to clarify the genetic mechanisms of BP and findings may prove more robust through increased use of designs that incorporate the complex nature of BP. We agree with Hayden that future study should take into account interactive effects among genes, because BP is a complex disease, likely to result from the effect of multiple genes interacting with each other. Again, evidence suggest that environmental factors play a significant role in the development 366 and course of the illness, 367 thus future studies are required to take into account individual psychosocial variables that may interact with liability genes for BP. We also agree with Hayden on the fact that genetic research on BP would also benefit from the investigation of endophenotypes associated with the disease. This is of particular benefit when controversial results are obtained in different studies, leading to the idea that a particular gene may be involved in some aspect related to the disorder, but not to the disorder per se. 368 In fact, gene variants may exert a broad effect on plural aspects of human behavior, in both its normal and pathological expressions. An example of this broad effect is the variant within the serotonin transporter gene (SERTPR), which affect a number of features, such as neuroanatomy, personality, way to react to stressors, social adjustment, anxiety and depressive symptoms, response to pharmacological treatments and many other features. 369 In conclusion, in the present review we summarized findings derived from linkage and association studies on BP, with the aim to point out genomic regions of interest and promising genes that have to be further investigated. The different nature of systems involved makes it difficult to hypothesize at present a unitary pathophysiology pathway. Because of the complex nature of BP, different approaches will probably be necessary to clarify the genetic mechanisms of BP.
